A detailed history of Hhlr Advisors, Ltd. transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Hhlr Advisors, Ltd. holds 5,176,906 shares of BGNE stock, worth $1.12 Billion. This represents 19.1% of its overall portfolio holdings.

Number of Shares
5,176,906
Previous 5,176,906 -0.0%
Holding current value
$1.12 Billion
Previous $810 Million 8.77%
% of portfolio
19.1%
Previous 17.98%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

SELL
$178.3 - $266.78 $52.7 Million - $78.8 Million
-295,353 Reduced 5.4%
5,176,906 $923 Million
Q3 2019

Nov 14, 2019

BUY
$120.61 - $148.29 $125 Million - $153 Million
1,034,306 Added 23.31%
5,472,259 $670 Million
Q4 2018

Feb 14, 2019

BUY
$107.01 - $175.15 $475 Million - $777 Million
4,437,953 New
4,437,953 $622 Million

Others Institutions Holding BGNE

About BeiGene, Ltd.


  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $22.5B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Hhlr Advisors, Ltd. Portfolio

Follow Hhlr Advisors, Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hhlr Advisors, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Hhlr Advisors, Ltd. with notifications on news.